Targeting Bruton's tyrosine kinase in B cell malignancies.
Rotterdam, Netherlands. In Nat Rev Cancer, 24 Apr 2014
Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.
Update on the Biology and Treatment Options for Hairy Cell Leukemia.
Houston, United States. In Curr Treat Options Oncol, 21 Apr 2014
Ongoing and planned clinical trials are assessing various treatment strategies, such as the combination of purine analogues and various anti-CD20 monoclonal antibodies, recombinant immunotoxins targeting CD22 (e.g., moxetumomab pasudotox), BRAF inhibitors, such as vemurafenib, and B-cell receptor signaling inhibitors, such as ibrutinib, which is a Bruton's tyrosine kinase inhibitor.
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.
Los Angeles, United States. In Nat Rev Immunol, Aug 2013
Indeed, the encouraging results of several ongoing clinical trials that target the activity of phosphoinositide 3-kinase δ-isoform (PI3Kδ), Bruton tyrosine kinase (BTK) or spleen tyrosine kinase (SYK) downstream of the BCR highlight the therapeutic potential of inhibiting BCR signalling.
The CLL cell microenvironment.
Houston, United States. In Adv Exp Med Biol, 2012
This chapter summarizes current knowledge about cellular and molecular interactions between CLL cells and their supportive tissue microenvironment and the therapeutic targets that are emerging, focusing on the CXCR4-CXCL12 axis and small molecule inhibitors that are targeting the B cell receptor-associated kinases SYK, BTK, and PI3Kδ.
Ibrutinib and novel BTK inhibitors in clinical development.
Valhalla, United States. In J Hematol Oncol, 2012
Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.